Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (currently amended) A composition dosage form comprising a shell portion that comprises a composition comprising 40 to 95 weight percent of a high molecular weight, water soluble polymer having a cloud point from about 20 to about 90° C, 5 to 25 weight percent carrageenan, and 0.5 to 5 weight percent gellan gum.
- 2. (currently amended) The <u>dosage formeomposition</u> of claim 1, wherein the high molecular weight, water soluble polymer is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, and mixtures thereof.
- 3. (currently amended) The <u>dosage formeomposition</u> of claim 2, wherein the high molecular weight, water soluble polymer comprises hydroxypropyl methylcellulose having a viscosity from about 80 to about 120,000 mPa s in 2% aqueous solution.
- 4. (currently amended) The <u>dosage formeomposition</u> of claim 1, further comprising an inorganic cation.
- 5. (currently amended) The <u>dosage formeomposition</u> of claim 14, wherein the inorganic cation is selected from the group consisting of potassium cations, calcium cations, and mixtures thereof.
- 6. (currently amended) The <u>dosage formeomposition</u> of claim 1, further comprising a lubricant.
- 7. (currently amended) The <u>dosage formeomposition</u> of claim 16, wherein the lubricant is glyceryl monostearate.

8. (currently amended) The <u>dosage formeomposition</u> of claim 1 <u>wherein the shell portion</u> is in solid form and <u>is</u> substantially free of pores having a diameter of 0.5 to 5.0 microns.

Cancel claims 9-12.

13. (currently amended) A dosage form comprising the composition of claim 1 according to claim 1 and further comprising an pharmaceutical active ingredient, wherein said pharmaceutical active ingredient is released from the dosage form in a burst release fashion.

Cancel claims 14-16.

- 17. (currently amended) A composition dosage form comprising a shell portion that comprises a composition comprising 40 to 95 weight percent of a high molecular weight, water soluble polymer having a cloud point from about 20 to about 90° C, 5 to 40 weight percent of one or more carrageenans, and 0.5 to 30 weight percent lubricant.
- 18. (currently amended) The <u>dosage formeomposition</u> of claim 17, wherein the high molecular weight, water soluble polymer is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, and mixtures thereof.
- 19. (currently amended) The <u>dosage formeomposition</u> of claim 18, wherein the high molecular weight, water soluble polymer comprises hydroxypropyl methylcellulose having a viscosity from about 80 to about 120,000 mPa s in 2% aqueous solution.
- 20. (currently amended) The <u>dosage formeomposition</u> of claim 17, further comprising an inorganic cation.
- 21. (currently amended) The <u>dosage formeomposition</u> of claim <u>1720</u>, wherein the inorganic cation is selected from the group consisting of potassium cations, calcium cations, and mixtures thereof.

- 22. (currently amended) The <u>dosage formeomposition</u> of claim 17, wherein the lubricant is glyceryl monostearate.
- 23. (currently amended) The <u>dosage formeomposition</u> of claim 17 in solid form and substantially free of pores having a diameter of 0.5 to 5.0 microns.

Cancel claims 24-27.

28. (currently amended) A dosage form emprising the composition of claim 17 and according to claim 17 further comprising an pharmaceutical active ingredient, wherein said pharmaceutical active ingredient is released from the dosage form in a burst release fashion.

29-31 cancel